US5820868A
(en)
|
1993-12-09 |
1998-10-13 |
Veterinary Infectious Disease Organization |
Recombinant protein production in bovine adenovirus expression vector system
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US6420629B1
(en)
*
|
1996-09-09 |
2002-07-16 |
B.C. Research Inc. |
Process of increasing plant growth and yield and modifying cellulose production in plants
|
US7732129B1
(en)
|
1998-12-01 |
2010-06-08 |
Crucell Holland B.V. |
Method for the production and purification of adenoviral vectors
|
KR100503701B1
(ko)
|
1996-11-20 |
2005-07-26 |
인트로겐 테라페티스, 인코퍼레이티드 |
아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
|
DE69838644T2
(de)
|
1997-06-23 |
2009-05-14 |
The University Of Saskatchewan |
Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
|
CA2324440A1
(en)
*
|
1998-03-28 |
1999-10-07 |
University Of Utah Research Foundation |
Directed antisense libraries
|
US6670188B1
(en)
*
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
CN1342206A
(zh)
|
1998-08-28 |
2002-03-27 |
杜克大学 |
在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
|
US6303362B1
(en)
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
DE1221490T1
(de)
*
|
1999-09-17 |
2003-05-28 |
Tgt Lab S A De C V |
Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben
|
FR2799472B1
(fr)
*
|
1999-10-07 |
2004-07-16 |
Aventis Pharma Sa |
Preparation d'adenovirus recombinants et de banques adenovirales
|
US6867022B1
(en)
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
US6998263B2
(en)
|
2000-02-09 |
2006-02-14 |
Genvec, Inc. |
Methods of preparing and using a viral vector library
|
US6830920B2
(en)
*
|
2000-03-08 |
2004-12-14 |
University Of Iowa Research Foundation |
Rapid generation of recombinant adenoviral vectors
|
AU2001263689B2
(en)
*
|
2000-05-31 |
2007-03-22 |
University Of Saskatchewan |
Modified bovine adenovirus having altered tropism
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
EP1317560A4
(de)
*
|
2000-09-08 |
2005-10-05 |
Gen Hospital Corp |
Sich selbst neuordnende dna vektoren(18.03.02)
|
US6447995B1
(en)
|
2000-10-04 |
2002-09-10 |
Genvec, Inc. |
Utilizing intrinsic fluorescence to detect adenovirus
|
GB0027501D0
(en)
*
|
2000-11-10 |
2000-12-27 |
Astrazeneca Ab |
Vector
|
JP2004513638A
(ja)
*
|
2000-11-10 |
2004-05-13 |
アストラゼネカ・アクチエボラーグ |
ベクター
|
MXPA00011713A
(es)
*
|
2000-11-28 |
2002-05-31 |
Tgt Lab S A De C V |
Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
US20020177229A1
(en)
*
|
2001-01-19 |
2002-11-28 |
Ivo Piest |
Swap/counter selection: a rapid cloning method
|
WO2003025161A1
(en)
|
2001-09-18 |
2003-03-27 |
Clontech Laboratories, Inc. |
Site-specific recombinase based method for producing adenoviral vectors
|
AU2003210661A1
(en)
*
|
2002-01-24 |
2003-09-02 |
Novartis Ag |
Fiber shaft modifications for efficient targeting
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
JP2005536231A
(ja)
*
|
2002-05-08 |
2005-12-02 |
イントロン,インコーポレーテッド |
アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用
|
CA2899360A1
(en)
|
2002-08-21 |
2004-04-08 |
Revivicor, Inc. |
Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
|
CA2500270A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Powderject Research Limited |
Nucleic acid constructs for gene expression
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
WO2005001133A2
(en)
*
|
2003-06-03 |
2005-01-06 |
Collateral Therapeutics, Inc. |
Compositions and methods for high throughput construction and functional analysis of expression libraries
|
MXPA05013234A
(es)
*
|
2003-06-10 |
2006-03-09 |
Univ Saskatchewan |
Proteinas de capside de adenovirus quimericas.
|
US20070213288A1
(en)
*
|
2003-07-17 |
2007-09-13 |
University Of South Florida |
Adenoviral Vector Capable of Infecting Tumor Cells and Eliminating the Function of STAT3
|
US7897146B2
(en)
*
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
WO2005049846A2
(en)
*
|
2003-11-17 |
2005-06-02 |
Crusade Laboratories Limited |
Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
|
GB0326798D0
(en)
*
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
JP2007518423A
(ja)
*
|
2004-01-23 |
2007-07-12 |
イントロン、インコーポレイテッド |
スプライセオソーム仲介型rnaトランススプライシングを使用するアポa−1及びその変異体の発現
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
US8053232B2
(en)
*
|
2004-01-23 |
2011-11-08 |
Virxsys Corporation |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
|
JP2008507294A
(ja)
|
2004-07-26 |
2008-03-13 |
ダウ グローバル テクノロジーズ インコーポレイティド |
菌株遺伝子操作による改善されたタンパク質発現のための方法
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
EP1771571A2
(de)
*
|
2004-07-30 |
2007-04-11 |
Targeted Genetics Corporation |
Impfungsmethode basierend auf rekombinant aav
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
US7879321B2
(en)
*
|
2004-10-08 |
2011-02-01 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
CA2586107A1
(en)
|
2004-11-03 |
2006-05-18 |
Introgen Therapeutics Inc. |
A novel method for the production and purification of adenoviral vectors
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
KR20080052512A
(ko)
*
|
2005-05-23 |
2008-06-11 |
박신, 인크. |
아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
|
AU2006292827B2
(en)
|
2005-08-09 |
2013-02-14 |
Revivicor, Inc. |
Transgenic ungulates expressing CTLA4-IG and uses thereof
|
KR100723009B1
(ko)
*
|
2005-11-30 |
2007-05-29 |
한국원자력연구원 |
인간 p31 유전자를 함유하는 악성 종양 치료용 약학적조성물
|
UA97479C2
(ru)
|
2006-04-11 |
2012-02-27 |
Арена Фармасьютикалз, Инк. |
Применение g-белок-связанного рецептора (gpcr) для идентификации средств, которые усиливают секрецию глюкозозависимого инсулинотропного пептида (gi)
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EP1900749A1
(de)
|
2006-09-12 |
2008-03-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
|
US8052968B2
(en)
|
2006-10-16 |
2011-11-08 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
DE102006060799A1
(de)
*
|
2006-12-21 |
2008-06-26 |
RUHR-UNIVERSITäT BOCHUM |
RSV F-Protein und seine Verwendung
|
AU2008245696B2
(en)
|
2007-04-27 |
2013-11-07 |
Pelican Technology Holdings, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
EP2171071B1
(de)
*
|
2007-06-15 |
2015-08-05 |
Genelux Corporation |
Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
|
EP2612868B1
(de)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunsuppressive Polypeptide und Nucleinsäuren
|
EP2108960A1
(de)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
|
EA201301173A1
(ru)
|
2011-04-15 |
2015-08-31 |
Дженелюкс Корпорейшн |
Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
CN111549065B
(zh)
*
|
2020-04-01 |
2023-11-24 |
广州医科大学附属第一医院(广州呼吸中心) |
应用腺病毒转导制备能够表达人源apn转基因非人动物的方法,及所得动物的应用
|
US20240033347A1
(en)
|
2022-07-08 |
2024-02-01 |
Viromissile, Inc. |
Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
|